HER2 Support Group Forums - View Single Post - ?reason to look for androgen-receptors on ER-PR- breast cancers?

Lani · 05-02-2006, 10:00 PM

Survival rate of patients with er+pr+ tumors is 15% greater than those who are er-pr---advantage attribuated to antihormone therapy.

Approx. 33% of breast cancers are hormone insensitive lacking both er and pr. Androgen receptor is the most common receptor present in breast cancers--present in 66% to 80% of tumors. AR status is easily determined by IHC, but is neither routinely assayed nor used for treatment planning.
Their results indicated 42% of er-pr-tumors are A+. SEVERAL STUDIES FOUND ASSOCIATION BETWEEN AR EXPRESSION AND SURVIVAL IN PTS WITH ER- TUMORS.
HE SUGGESTS TREATMENTS WHICH EXPLOIT THE USE OF AR OR CONFER INCREASED AR SENSITIVITY TO DRUGS TO IMPROVE THE PROGNOSIS OF PTS WITH ER-PR- BREAST CANCER. EVEN IF AR IS ONLY WEAKLY EXPRESSED GROWTH INHIBITION SEEMS TO BE POSSIBLE WITH DHEA AND AIS. THE COMBINATION LED TO CELL DEATH IN ER-PR- TUMORS AS LONG AS THERE WAS A THRESHOLD LEVEL OF AR

THIRD GENERATION AIS PREVENTED DHEA BEING CONVERTED TO ESTRONE AND THUS LED TO EVEN MORE DHEA BEING AVAILABLE TO INHIBIT THE ANDROGEN RECEPTOR

05-02-2006, 10:00 PM	#6
Lani Senior Member Join Date: Mar 2006 Posts: 4,783	it won't let me excerpt from original paper so I will summarize Survival rate of patients with er+pr+ tumors is 15% greater than those who are er-pr---advantage attribuated to antihormone therapy. Approx. 33% of breast cancers are hormone insensitive lacking both er and pr. Androgen receptor is the most common receptor present in breast cancers--present in 66% to 80% of tumors. AR status is easily determined by IHC, but is neither routinely assayed nor used for treatment planning. Their results indicated 42% of er-pr-tumors are A+. SEVERAL STUDIES FOUND ASSOCIATION BETWEEN AR EXPRESSION AND SURVIVAL IN PTS WITH ER- TUMORS. HE SUGGESTS TREATMENTS WHICH EXPLOIT THE USE OF AR OR CONFER INCREASED AR SENSITIVITY TO DRUGS TO IMPROVE THE PROGNOSIS OF PTS WITH ER-PR- BREAST CANCER. EVEN IF AR IS ONLY WEAKLY EXPRESSED GROWTH INHIBITION SEEMS TO BE POSSIBLE WITH DHEA AND AIS. THE COMBINATION LED TO CELL DEATH IN ER-PR- TUMORS AS LONG AS THERE WAS A THRESHOLD LEVEL OF AR THIRD GENERATION AIS PREVENTED DHEA BEING CONVERTED TO ESTRONE AND THUS LED TO EVEN MORE DHEA BEING AVAILABLE TO INHIBIT THE ANDROGEN RECEPTOR